End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4384 USD | +2.62% | +3.89% | -10.00% |
30/04 | Akili, Inc. Plans to Continue to Pursue Marketing Authorization from the U.S. Food and Drug Administration for Its EndeavorOTC Product | CI |
30/04 | Akili, Inc. to Reduce Workforce | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration1st Jan change | Capi. | |
---|---|---|
-10.00% | 3.45Cr | |
+11.55% | 23TCr | |
+10.67% | 19TCr | |
+13.40% | 14TCr | |
+25.81% | 11TCr | |
+0.80% | 6.36TCr | |
+5.62% | 5.13TCr | |
+13.12% | 5.1TCr | |
+7.61% | 4.33TCr | |
+5.21% | 3.7TCr |
- Stock Market
- Equities
- AKLI Stock
- News Akili, Inc.
- Morgan Stanley Initiates Akili at Equalweight With $2 Price Target